Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

afr.com - Michael Smith - Big pharma eyes Australian biotech as $300b patent cliff looms
Big pharma eyes Australian biotech as $300b patent cliff looms
Australian Financial Review

When Swiss pharmaceutical giant Novartis paid more than $2 billion for cancer therapy company Myricx last month, it was a wake-up call for Australian venture capital and superannuation funds which have had mixed luck with the notoriously risky…

thehindubusinessline.com - Fosun Pharma sells 4.55% stake in Gland Pharma for Rs 2,121 crore
Fosun Pharma sells 4.55% stake in Gland Pharma for Rs 2,121 crore
BusinessLine

Chinese pharmaceutical major Fosun Pharma has pared its holding in Gland Pharma by selling a 4.5 per cent stake for Rs 2,121 crore through separate block deals on BSE. Fosun Pharma Industrial Pte Ltd, one of the promoters of Gland Pharma, offloaded…

marketbeat.com - Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of 'Moderate Buy' by Brokerages
Avalyn Pharma Inc. (NASDAQ:AVLN) Given Average Rating of 'Moderate Buy' by Brokerages
MarketBeat

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Get Free Report) have received an average rating of 'Moderate Buy' from the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with…

newsbytesapp.com - Dwaipayan Roy - Chinese pharma major sells 4.55% Gland Pharma stake for ₹2,121cr
Chinese pharma major sells 4.55% Gland Pharma stake for ₹2,121cr
NewsBytes

What's the story Fosun Pharma, a leading Chinese pharmaceutical company, has sold a 4.55% stake in Hyderabad -based Gland Pharma for ₹2,121.50 crore. The sale was executed through multiple block deals on the Bombay Stock Exchange (BSE).

marketbeat.com - Bank of New York Mellon Corp Buys New Position in Urogen Pharma $URGN
Bank of New York Mellon Corp Buys New Position in Urogen Pharma $URGN
MarketBeat

Bank of New York Mellon Corp purchased a new position in shares of Urogen Pharma (NASDAQ:URGN - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional…

thestandard.com.hk - The Standard 英文虎報 - Fosun to repurchase H shares with proposed amount up to $1 billion
Fosun to repurchase H shares with proposed amount up to $1 billion
The Standard

Fosun International (0656) to repurchase H shares of the company, with the proposed total amount of funds for repurchasing H Shares of up to HK$1 billion. SCROLL TO CONTINUE WITH CONTENT The use of such repurchased H shares will be decided by the…

philipmcmillan.substack.com - Dr Philip McMillan - The Hard COVID Questions That Protect Pharma
The Hard COVID Questions That Protect Pharma
Vejon COVID-19 Review

The most important person in a pharmaceutical company may be the one willing to say no (timecodes below). That is what I took from my latest conversation with Susan F. Langlois, a retired vaccine-industry regulatory affairs specialist with…

thetruthaboutcancerofficial.substack.com - The Kratom Conspiracy: Why Big Pharma Wants to Ban Nature's Answer to Opioids
The Kratom Conspiracy: Why Big Pharma Wants to Ban Nature's Answer to Opioids
The Truth About Cancer

n the 1930s, a coordinated campaign of racist propaganda and corporate greed turned a revered medicinal plant into a Schedule I “drug” with no recognized medical value. The target was cannabis. The architects were lumber baron William…

seekingalpha.com - Albert Anthony - Invesco Mortgage Capital Remains A High-Yield REIT Idea, As MBS Portfolio Grows (NYSE:IVR)
Invesco Mortgage Capital Remains A High-Yield REIT Idea, As MBS Portfolio Grows (NYSE:IVR)
Seeking Alpha

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

fool.com - Keith Speights - Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
The Motley Fool

The adage that 'birds of a feather flock together' doesn't always apply to billionaire investors. Most of these super-successful individuals have their own unique strategies that are highly differentiated from other approaches. However, that…

thehindubusinessline.com - Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets
Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets
BusinessLine

Pharma company Novartis India Ltd (NIL) plans to pursue disciplined, therapy-aligned acquisitions and deepen its last-mile reach into Tier 2 and Tier 3 markets to drive its next phase of growth, according to the company's annual report. The…

marketbeat.com - Saudi Central Bank Increases Stock Position in Pfizer Inc. $PFE
Saudi Central Bank Increases Stock Position in Pfizer Inc. $PFE
MarketBeat

Saudi Central Bank raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 23.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 976,902 shares…

cyclingweekly.com - Joseph Lycett - Marco Brenner triumphs on stage 14 summit finish at the Vuelta a España as Enric Mas strengthens GC lead
Marco Brenner triumphs on stage 14 summit finish at the Vuelta a España as Enric Mas strengthens GC lead
Cycling Weekly

Another challenging mountaintop finish saw Marco Brenner (Tudor Pro Cycling) emerge victorious atop the Sierra de la Pandera on stage 14 of the Vuelta a España. The German rider faced stiff competition from the current polka-dot jersey…

marketbeat.com - Rose Capital Advisors LLC Invests $905,000 in Pfizer Inc. $PFE
Rose Capital Advisors LLC Invests $905,000 in Pfizer Inc. $PFE
MarketBeat

Rose Capital Advisors LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 37,580 shares of the biopharmaceutical company's stock…

thejournal.ie - Ralph Benson - Financial analyst on ECB hike: Interest rates are rising... what should you do?
Financial analyst on ECB hike: Interest rates are rising... what should you do?
TheJournal.ie

DONE WELL, CENTRAL banking is pretty bland stuff. No surprises. Such is the case for next week's European Central Bank announcement on interest rates. The people in grey suits are scheduled to spend two days in meetings, emerging at lunchtime on…

Receive a Daily briefing on Pharma Industry News

Get Started